Rheumnow Podcast ACR24 - JAK_TYK2
Nov 23, 2024
Richard Conway, a vasculitis specialist, discusses pivotal findings from ACR 2024. Peter Nash delves into the role of JAK inhibitors, while Janet Pope reviews treatment strategies for polymyalgia rheumatica and giant cell arteritis. Eric Dian analyzes intriguing oral abstracts on rheumatoid arthritis, and David Liu emphasizes cardiovascular risks associated with treatments. They explore the safety of JAKs, advances in managing RA during COVID-19, and the efficacy of new therapies for PMR and GCA, showcasing innovative strategies for improving patient outcomes.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8
Intro
00:00 • 2min
Upcoming Recaps and Educational Content from ACR
01:47 • 2min
Advancements in Psoriatic Arthritis Treatments
03:48 • 7min
Managing RA Patients During COVID-19 Vaccinations
10:42 • 12min
Recent Advances in PMR and RA Treatment
23:02 • 17min
Subgroup Analysis of Upatacitinib in Giant Cell Arteritis
40:03 • 5min
Evaluating the Safety of JAK Inhibitors in Treatment
45:14 • 2min
Advancements in JAK Inhibitors for Inflammatory Diseases
47:09 • 25min